Is Monitoring of Cytomegalovirus Disease Required in Nontransplant Pediatric Acute Lymphoblastic Leukemia?

Simple item page
dc.contributor.authorŞen S.
dc.contributor.authorÖzdemir H.H.
dc.contributor.authorKaradaş N.
dc.contributor.authorBal Z.Ş.
dc.contributor.authorGöktepe Ş.Ö.
dc.contributor.authorEce D.
dc.contributor.authorBalkan C.
dc.contributor.authorAydinok Y.
dc.contributor.authorKarapinar D.Y.
dc.date.accessioned2024-07-22T08:05:42Z
dc.date.available2024-07-22T08:05:42Z
dc.date.issued2021
dc.description.abstractIntroduction: Cytomegalovirus (CMV) infections in developing countries are experienced at an early age. This study was performed to investigate the frequency of reactivation and risk factors of infection acquired at an early age of nontransplant acute lymphoblastic leukemia (ALL) patients receiving immunosuppressive therapy with weekly monitoring of CMV levels in Turkey. Materials and Methods: This was a retrospective, single-center study of 172 pediatric patients (102 boys and 70 girls) with ALL. All patients were monitored routinely for CMV-DNA at the initial presentation of leukemia and twice a week during chemotherapy. The CMV immunoglobulin (Ig)M/IgG titers were measured at admission. Results: CMV seropositivity at baseline was 90,11%. The overall prevalence of CMV infection (viremia) was 70.34%, 116 of whom were seropositive for CMV IgG and 5 of whom were negative for CMV at the time of ALL diagnosis. Reactivation was more common than de novo CMV infections (P=0.000). CMV seropositivity at the beginning of the leukemia diagnosis was found to be an independent predictor for developing CMV infection (P=0.001). A total of 60 CMV infection episodes were treated with antivirals. Four of these included organ involvement. The duration of CMV-DNA viremia episodes was longer in patients with CMV-DNA ≥1000 copies/mL (n=45) than in those with lower CMV-DNA levels (P=0.002). Infection was shown not to be associated with chemotherapy phase. Conclusion: This study suggests the importance of monitoring for CMV infections in developing countries because of frequent reactivations in seropositive ALL patients. It should be kept in mind that low CMV-DNA levels may also lead to organ involvement. © 2021 Lippincott Williams and Wilkins. All rights reserved.
dc.identifier.DOI-ID10.1097/MPH.0000000000002272
dc.identifier.issn10774114
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13231
dc.language.isoEnglish
dc.publisherLippincott Williams and Wilkins
dc.subjectAdolescent
dc.subjectAntibodies, Viral
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectCross-Sectional Studies
dc.subjectCytomegalovirus
dc.subjectCytomegalovirus Infections
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHospitalization
dc.subjectHumans
dc.subjectImmunoglobulin G
dc.subjectImmunosuppression Therapy
dc.subjectMale
dc.subjectPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subjectPrevalence
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectTurkey
dc.subjectViremia
dc.subjectganciclovir
dc.subjectimmunoglobulin G
dc.subjectimmunoglobulin M
dc.subjectvalganciclovir
dc.subjectvirus DNA
dc.subjectimmunoglobulin G
dc.subjectvirus antibody
dc.subjectacute lymphoblastic leukemia
dc.subjectArticle
dc.subjectcancer diagnosis
dc.subjectchild
dc.subjectcross-sectional study
dc.subjectCytomegalovirus
dc.subjectcytomegalovirus infection
dc.subjectdisease duration
dc.subjectfemale
dc.subjectfrequency
dc.subjecthigh risk population
dc.subjecthuman
dc.subjectimmunosuppressive treatment
dc.subjectinfant
dc.subjectmaintenance therapy
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedian risk group
dc.subjectnonhuman
dc.subjectpatient monitoring
dc.subjectpopulation
dc.subjectpredictor variable
dc.subjectprevalence
dc.subjectrecurrent infection
dc.subjectretrospective study
dc.subjectrisk factor
dc.subjecttreatment duration
dc.subjecttreatment response
dc.subjectTurkey (republic)
dc.subjectvirus reactivation
dc.subjectacute lymphoblastic leukemia
dc.subjectadolescent
dc.subjectblood
dc.subjectclinical trial
dc.subjectcomplication
dc.subjectcytomegalovirus infection
dc.subjectfollow up
dc.subjectgenetics
dc.subjecthospitalization
dc.subjectimmunology
dc.subjectisolation and purification
dc.subjectpreschool child
dc.subjectprognosis
dc.subjectturkey (bird)
dc.subjectviremia
dc.subjectvirology
dc.titleIs Monitoring of Cytomegalovirus Disease Required in Nontransplant Pediatric Acute Lymphoblastic Leukemia?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu